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Abstract 
Rapid detection of patients with carbapenem-producing Enterobacteriaceae (CPE) is essential 
for the prevention of nosocomial cross-transmission, allocation of isolation facilities and to 
protect patient safety. Here, we aimed to design a new laboratory work-flow, utilising 
existing laboratory resources, in order to reduce time-to-diagnosis of CPE. A review of the 
current CPE testing processes and of the literature was performed to identify a real-time 
commercial polymerase chain reaction (PCR) assay that could facilitate batch testing of CPE 
clinical specimens, with adequate CPE gene coverage. Stool specimens (210) were collected; 
CPE-positive inpatients (n=10) and anonymised community stool specimens (n=200). Rectal 
swabs (eSwab™) were inoculated from collected stool specimens and a manual DNA 
extraction method (QIAamp
®
 DNA Stool Mini Kit) was employed. Extracted DNA was then 
processed on the Check-Direct CPE
® assay. The three step process of making the eSwab™, 
extracting DNA manually and running the Check-Direct CPE® assay, took <5 minutes, 1 
hour 30 minutes and 1 hour 50 minutes, respectively. It was time efficient with a result 
available in under 4 hours, comparing favourably with the existing method of CPE screening; 
average time-to-diagnosis of 48/72 hours. Utilising this CPE work-flow would allow a ‘same-
day’ result. Antimicrobial susceptibility testing results, as is current practice, would remain a 
‘next-day’ result.  In conclusion, the Check-Direct CPE® assay was easily integrated into a 
local laboratory work-flow and could facilitate a large volume of CPE screening specimens in 
a single batch, making it cost-effective and convenient for daily CPE testing.  
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Introduction 
Carbapenemase-producing Enterobacteriaceae (CPE) are prevalent worldwide in all areas of 
healthcare, with isolates and outbreaks reported in acute care facilities
1-4 
including 
neonatology and paediatrics,
5, 6
 respite/convalescence facilities
7
 and long-term care facilities.
8
 
Early detection and infection control strategies are key factors for successfully restricting 
onward transmission of CPE.
9
 The Mid-West of Ireland has the highest rates of CPE in 
Ireland with 140 first isolates detected between 2009 and 2015, predominantly Klebsiella 
pneumoniae carbapenemase (KPC)-producing Enterobacteriacea (n=123).
10
 For clinicians 
and antimicrobial pharmacists, CPE pose a major challenge at the bedside as they 
significantly limit antimicrobial prescribing.
11
 Morbidity and  mortality are both increased in 
CPE infections, particularly bloodstream and respiratory infections,
12
 with mortality rates 
ranging from 38-57%,
9
 and poor outcomes in survivors,
13-15
 emphasising the need for 
commencement of timely targeted antimicrobial therapy to increase patient survival.  
 
Culture-based techniques using selective agars for the identification of CPE detect 
carbapenem-resistant organisms with minimal laboratory ‘hands on’ bench time, but they 
cannot differentiate either the carbapenemase type or the Enterobacteriaceae species present 
with additional phenotypic and/or molecular testing required.
16, 17
  Within our laboratory, our 
current CPE screening process, utilising selective chromogenic agar (CHROMagar™ KPC, 
Paris, France) and GeneXpert
®
 Carba-R for in-house molecular confirmation of CPE positive 
specimens (Cepheid, Buckinghamshire, United Kingdom), had an average turnaround time of 
48/72 hours from specimen arrival in the laboratory to final CPE result for the clinician. The 
48/72 hour delay in diagnosis was in keeping with other centres worldwide using selective 
cultures,
18-20
 but was resulting in use of empiric broad-spectrum antimicrobials and an 
inefficient use of limited isolation facilities. 
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PCR-based techniques, facilitating direct testing from rectal swabs, have demonstrated 
efficiencies in the identification of CPE-positive isolates and a welcome reduction in 
laboratory turnaround time.
21
 Our aim was to establish, under usual laboratory working 
conditions and current available resources, how quickly a CPE diagnosis could be reached in-
house from the time of receipt of the clinical specimen in the laboratory to a CPE result. The 
workflow was designed to utilise direct screening from rectal swabs (eSwab™ 480CE, 
Copan, Italy), a manual DNA extraction method (QIAamp
®
 DNA Stool Mini Kit, Qiagen, 
United Kingdom) and the installation of the Check-Direct CPE
® 
assay onto an existing 
LightCycler
®
 480 Instrument (Roche Diagnostics Limited, United Kingdom). The Check-
Direct CPE
®
 assay (Check-Points, Wageningen, The Netherlands) enables the simultaneous 
detection of four of the most frequently detected carbapenemase enzymes (blaKPC, blaOXA-48, 
blaVIM and blaNDM) using direct testing from rectal swabs, and has been shown to reduce time-
to-diagnosis with good sensitivity and specificity.
22
  
 
Previous publications using the Check-Direct CPE
® 
assay have utilised an automated DNA 
extraction methodology; NucliSENS
® 
easyMAG
® 
extraction kit, bioMérieux, France.
23-25
 To 
the best of our knowledge, this is the first report of the use of a manual DNA extraction 
method with the heck-Direct CPE
® 
assay. 
 
Results  
Epidemiological 
From 195 anonymised community samples that underwent further processing, 58% (n=112) 
were from females. The median age of positive patients was 62.4 years (range 20-94 years). 
186 samples (95%) were from general practitioner clinics from patients living in community 
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dwellings. Nine stool samples were received from long-term care facilities (LTCF) of which 
six were public institutions.  
 
Technical  
A significant improvement in time-to-diagnosis versus the existing culture-based processes 
employed in the laboratory was demonstrated using our newly designed CPE laboratory 
workflow. The three step process of making the eSwab™, extracting DNA manually and 
running the Check-Direct CPE® assay, taking <5 minutes, 1 hour 30 minutes, 1 hour 50 
minutes respectively, was time efficient with a result available in under 4 hours. A key factor 
in the ability to provide a result in under 4 hours was no delay in waiting to use the 
Lightcycler
®
 instrument. While our process of making the eSwab™ was used as a surrogate 
for rectal swabs taken from patients, the time taken to perform a rectal swab on a patient is 5-
7 minutes following our local standard operating procedure (SOP). When the time taken to 
transport the rectal swabs from clinical areas to the laboratory is accounted for, usually 10-20 
minutes depending on time of day, a CPE results was still possible in under 4 hours. 
Antimicrobial susceptibility testing and an Enterobacteriaceae species identification using 
MALDI-TOF MS is still necessary on any positive isolate identified on the Check-Direct 
CPE
® 
assay.  
 
The Check-Direct CPE® assay was able to process larger batches of clinical specimens in 
comparison to the GeneXpert® Carba-R, making it suitable for use as part of a CPE 
screening programme. The assay was user-friendly and the interface on the Lightcycler
®
 was 
easy to navigate. For clinicians and scientists with no previous or limited PCR experience, the 
pre-PCR sample preparatory steps required minimal hands-on time, with all steps occurring 
in an intuitive fashion.  
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A challenge encountered with our new workflow was that DNA could not be extracted from a 
number of samples (n=45, 26%) when assessed on the SPECTROstar Nano LVis Plate. This 
was attributed to a combination of overly diluted samples and other inhibitory factors within 
the stool specimens such as trace elements of blood in the patient’s stool specimen or 
undigested food particles. Of the 45 stool specimens, 27% (n=12) were recorded as being a 
liquid consistency on collection, even before dilution. A review of the results from the other 
128 community specimens from which DNA was positively extracted displayed a mean DNA 
concentration of 38.6 ng/µl. Interestingly, 8% (n=10) of these specimens were also classified 
as having a liquid consistency on collection yet DNA extraction was possible. This was an 
indication of involvement of other inhibitory factors.  
 
Microbiological  
While the aim of this study was not primarily to identify new positive CPE cases, it is worth 
noting that no positive CPE isolates were detected from culture (n=390 plates; n=195 
COLOREX mSuperCARBA
™
, n=195 chromID
® 
CARBA SMART) following 24 hours 
incubation. One positive isolate (a KPC) was found using the Check-Direct CPE
® 
assay as 
shown in Figure 1. This specimen had a Ct value of 32.54, which fell within the positive 
specimen value range. 
 
Discussion 
Our aim in performing this study was to design a new laboratory-work flow, utilising existing 
laboratory physical and human resources, with the aim of expediting the diagnosis of CPE. 
The new laboratory work-flow we had designed achieved this objective. A major contributing 
factor to this improvement in time-to-detection was the use of testing directly from rectal 
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swabs, with the removal of traditional culturing processes, and the ability to perform 
screening using PCR in larger batches than previously using the GeneXpert
®
 Carba-R. From 
a clinical perspective, the old CPE workflow in use within the laboratory was suboptimal as 
the protracted time to diagnosis was leading to prolonged empiric broad-spectrum 
antimicrobial use pending CPE screening results, poor patient flow though the hospital, 
challenges in the allocation of scarce isolation facilities and unnecessary anxiety for patients 
in awaiting CPE screening results for a minimum of two days.  
 
By removing the use of selective chromogenic screening agar, which are historically labour 
intensive, with variable sensitivity,
26
 this reduced physical work within the laboratory 
associated with culturing, moving  agar plates from incubators to benches for further 
phenotypic and molecular testing. The availability of physical bench space for other 
laboratory routine work is also achieved as is the redeployment of scientists from culturing to 
other tasks.  
 
Rectal swabs are currently considered to be the most sensitive approach to detect colonisation 
with multi-drug resistant enteric Gram-negatives
8, 27
 but are wholly dependent on healthcare 
workers who are performing rectal swabbing at ward level ensuring the presence of visible 
faecal staining on the swab, as a surrogate markers for quality/amount of faecal material 
present, and in turn the likelihood of a good DNA yield on extraction. In this regard, any 
permanent move to direct testing from rectal swabs would require education to be provided to 
clinical ward staff. There are of course clinical scenarios where, despite the best efforts of 
those performing rectal swabs, rectal swabbing can be very challenging, for example, in 
patients with a large body mass index and those who are highly dependent with minimal 
independent mobility, it is often a perineum swab that is received. The minimal storage 
 9 
 
requirements of the eSwab™ makes them a more attractive sampling method also as they are 
slightly smaller in size than the rectal swabs currently used for screening.  
 
A consideration in selecting a commercial assay for this study was the range of CPE enzyme 
types detectable and an acceptance that no assay on the market at present has the ability to 
detect novel carbapenemases or to provide full coverage for all enzyme variants, in particular 
the OXA-48-like variants. Additionally, no assay as yet can provide an identification to 
Enterobacteriaceae species level. The most prevalent carbapenemases worldwide are IMP, 
VIM, OXA-48, NDM and KPC, with the latter three being most commonly identified in 
Ireland.
28
 The Check-Direct CPE
® 
assay had the ability to detect and differentiate between 
blaKPC, blaOXA-48, blaVIM and blaNDM, the same range as with the current GeneXpert® Carba-
R, but the larger volumes of sample that could be processed in each batch was an attractive 
feature of the Check-Direct CPE
® 
assay. In 2015, 9493 CPE screens were processed at UHL 
(average 792 per month), accounting for 20% of the laboratory workload, demonstrating our 
need for a cost-effective screening solution. A potential future problem that may emerge if 
the epidemiology of CPE in Ireland changes is that if more IMP isolates begin to appear 
within the region neither, the Check-Direct CPE
® 
assay  will not have capability to detect 
these isolates.  
 
From a practical perspective, consideration for the use of an automated DNA extraction 
method is perhaps warranted given the challenges encountered with the manual DNA 
extraction. Any extraction method employed must be able to successfully extract DNA from 
all consistencies of stool specimens for CPE testing. 
 
Conclusions 
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The accurate and timely detection of CPE is crucial for appropriate patient management and 
for the rapid implementation of infection prevention and control measures. The integration of 
a molecular commercial assay for batch CPE screening significantly reduces time-to-
detection. Changing an existing CPE work-flow must address the potential costs involved, 
annual numbers of CPE screens processed by the laboratory, CPE gene coverage and whether 
an automated DNA extraction system can be utilised to ensure optimal results.  
 
Patients and Methods 
Setting 
The Department of Clinical Microbiology at the University Hospital Limerick (UHL) 
provides a centralised microbiology service for six acute hospital sites and for general 
practitioners working within the area. Two full-time consultant microbiologists and one 
clinical microbiology specialist registrar are employed. The UHL laboratory team is 
comprised of 35 regular laboratory scientists in addition to two surveillance scientists. The 
hospital group serves a population of 400,000 people.  
 
Ethical approval  
Ethical approval to complete this study was granted by the HSE Mid-Western Regional 
Hospital Research Committee in December 2015.  
 
Existing microbiological and molecular methods for the detection of CPE  
CPE surveillance is currently performed on stool samples or rectal swabs. KPC selective 
chromogenic agar is used (CHROMagar™ KPC; Fannin, Catalog No. W11498) with an 
overnight incubation. MALDI-TOF MS (Bruker Diagnostics) identification is performed on 
all colonies, as previously described.
29
 Antimicrobial susceptibility testing is performed using 
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broth microdilution (ARIS Sensititre
®
 system (Thermo Fisher Scientific Inc, Masachusettts, 
USA).  Isolates with elevated carbapenem minimum inhibitory concentration (MIC), as per 
European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines, are 
further evaluated using the modified hodge test (MHT). Commercially available diagnostic 
kits consisting of meropenem discs supplemented with β-lactamase inhibitors meropenem + 
dipicolinic acid, meropenem + boronic acid and meropenem + cloxacillin (Rosco Diagnostica 
A/S; Catalog no. 98006) are used to phenotypically distinguish CPE isolates. In-house 
molecular confirmation is performed using GeneXpert
®
 Carba-R. 
 
A new CPE detection laboratory work-flow 
The Check-Direct CPE
® 
assay (Serosep, Catalog no. 18-0080) is a multiplex real-time PCR 
based on the TaqMan fast advanced molecular beacon technique with fluorescent DNA 
probes labelled with four different fluorophores (FAM, VIC, Texas Red or Cy5) for the 
detection of blaKPC, blaOXA-48, blaVIM and blaNDM and an internal extraction/inhibition control. 
This assay was installed onto an existing LightCycler
®
 480 PCR machine already in use 
within the laboratory for Entericbio realtime test panels (Serosep) for the detection of 
gastrointestinal pathogens. The Check-Direct CPE
® 
assay was validated prior to the 
commencement of this study using positive CPE clinical isolates obtained from a reference 
laboratory. 
 
The use of eSwabs™, a flocked nylon swab applicator (eSwab™ Copan; Medical Supply 
Company, Catalog no. 480CE), is recommended for performing direct testing from 
rectal/perianal swabs in the Check-Direct CPE
® 
user manual (Version 2.3, Issued 01-09-
2004).  At the time of this study, eSwabs™ were only approved for use within the hospital 
for environmental sampling. As a consequence, convenience duplicate rectal swabbing from 
 12 
 
patients could not be arranged to provide a sample for testing for the study. In order to obtain 
faecal material from which to extract DNA, a variety of stool specimens were collected, stool 
specimens from known CPE-positive inpatients (n=10) and anonymised community stool 
specimens (n=200). There were 195 community stool specimens were suitable for further 
analysis (Figure 1). Stools were classified on collection as either formed or of a liquid 
consistency. From these stool specimens, eSwabs™ were inoculated as per manufacturer’s 
instructions. Stoma bag samples were also accepted. Stools were collected over a four-week 
period. Each eSwab™ was inoculated from a fresh stool sample and frozen at -20 ˚C, pending 
further processing.  
 
The Check-Direct CPE
® 
user manual (Version 2.3, Issued 01-09-2004) specified that the 
Check-Direct CPE
® 
assay was validated for use using the NucliSENS
® 
easyMAG
® 
Extraction 
kit (bioMérieux). This automated DNA extraction system was not available within our 
laboratory. As an alternative, a manual DNA extraction method (QIAamp
®
 DNA Stool Mini 
Kit; Qiagen, Catalog no. 51504) was employed for DNA extraction following manufacturer’s 
guidelines (QIAamp
® 
DNA Stool Handbook 06/2012) with some modifications. Briefly, stool 
lysis buffer (Buffer ASL) was added to approximately 200 mg of frozen rectal swab diluted 
in liquid amies buffer (eSwab™) and mixed until homogenous. The sample was incubated at 
70 °C for 5 min followed by centrifugation as per the protocol. An InhibitEX tablet was 
added to the supernatant and vortexed until completely dissolved and mixed followed by 
centrifugation as per the manufacturer’s protocol. The supernatant was added to proteinase K; 
additional lysis buffer (Buffer AL) and 96% ethanol were subsequently added before 
incubation at 70 °C. DNA was then isolated following a series of centrifugations with 
QIAamp spin columns and buffer solutions. DNA was eluted in 100 µL elution buffer (Buffer 
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AE) and quantity and quality was assessed using a Spectrostar Nano plate reader LVis plate 
function (BMG Labtech). Extracted DNA was stored at -20 °C for subsequent PCR. 
 
With regard to pre-PCR sample preparation, 15 µl of the Check-Direct CPE
® 
assay PCR 
(qPCR) mix was added to each PCR well in-use. In addition, 10 µl of positive and 10 µl 
negative controls supplied with the kit, which already contained the internal control (a control 
DNA molecule provided as part of the kit), were used. Extracted DNA (known CPE positive 
or negative – 10 µL) was added to each well plus 5 µl of the internal control. DNA extracted 
from inpatient stool samples already confirmed as CPE positive were also used to confirm if 
our DNA extraction process could be used to extract CPE positive DNA.  Amplification 
curves were analysed using the ‘High Confidence’ option as recommended by the 
manufacturer examining for typical sigmoidal amplification seen with positive test results 
and cycle threshold (Ct) values were read.  
 
Opportunistically as large volumes of stool samples were being collected, it was decided to 
trial two new agar plates for the laboratory at this time also; COLOREX mSuperCARBA
™ 
(E&O Laboratories Ltd; Syntec, Catalog no. PP3095) and chromID
® 
CARBA SMART 
(bioMérieux, Catalog no. 414685). Culturing on these new agar plates also afforded a means 
of comparing the performance of the Check-Direct CPE
®
 assay. 
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Figure Legends 
 
Figure 1. Work flow for detection of carbapenemase-producing Enterobacteriaceae 
incorporation of two methods. 
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Table 1. Performance of two commercial CPE detection kits compared. 
 GeneXpert® Carba-R Check-Direct CPE
® 
assay on 
a LightCycler
®
 480 
Instrument 
 
Cost of one cartridge/kit 
(excluding VAT) 
€44.00 (ex-VAT) €950.50 (ex-VAT) 
 
Additional costs/kit needed  None QIAamp DNA Stool Mini 
kit for 50 extractions 
€220.00 (ex-VAT) 
 
Molecular method  Real-time PCR Real-time PCR 
Range of specimens that can 
be tested  
Bacterial culture,  rectal 
swabs/stool specimens 
Bacterial culture or rectal 
swabs/stool specimens 
Carbapenemase enzymes 
covered within the assay  
KPC, OXA-48, VIM, NDM, 
IMP 
KPC, OXA-48, VIM, NDM 
Carbapenemase enzymes not 
covered within the assay  
 IMP  
Pre-PCR hands-on 
preparation time  
<5 minutes <5 minutes 
Number of CPE clinical 
samples that can be 
performed simultaneously in 
one run 
4 (with current local 
machine set-up) 
96-well PCR plates used, 
therefore potentially 96 
specimens in one run 
Total assay run time  53 minutes  1 hour 50 minutes 
Time until result available 48/72 h < 4 h 
Number of samples that can 
be performed from one kit 
purchased as per 
manufacturer 
10 48 
 
VAT = value added tax  
PCR = polymerase chain reaction 
IMP = imipenem-hydrolyzing beta-lactamase 
KPC = Klebsiella pneumoniae carbapenemase 
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OXA-48 = Oxacillin-hydrolysing  
VIM = Verona integrin-encoded metallo beta-lactamases 
NDM = New Delhi metallo-beta-lactamase-1 
 
 
